How Does Visceral Fat Work?
Visceral fat is the adipose tissue stored around internal organs. This page outlines its formal classification, the pathways studied in relation to it, and the clinical research models in which it has been examined.
Visceral fat, also referred to as visceral adipose tissue (VAT) or intra-abdominal fat, is a metabolically active adipose depot stored around internal organs. It is distinct from subcutaneous fat, which lies beneath the skin. In the research literature, visceral fat is quantified by imaging methods such as magnetic resonance imaging (MRI), which can derive pancreatic proton density fat fraction (PDFF), and by bioelectrical impedance analysis (BIA), which yields a visceral fat measure alongside body fat percentage [1][4]. The depot is not a single molecular entity; it is a tissue compartment. Its study therefore centres on the adipokine and receptor signalling families that mediate its endocrine and inflammatory effects, including leptin, resistin, sclerostin, irisin, and the glucagon-like peptide-1 receptor (GLP-1R) pathway [3][6][11].
Visceral fat accumulation is associated with insulin resistance, type 2 diabetes, and cardiometabolic disease, and it can occur even in individuals with normal or mildly elevated body mass index [2][8][11]. The sections below summarise research studies that have examined visceral fat in specific populations and models.
Research Studies
Mazdutide and fatty pancreas in overweight or obesity
A randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial is evaluating mazdutide for improving fatty pancreas in patients with overweight or obesity. The study plans to enrol 194 participants, randomised 1:1 to mazdutide plus standardised lifestyle intervention or placebo plus standardised lifestyle intervention, for 48 weeks. The primary efficacy endpoint is change from baseline in pancreatic proton density fat fraction (PDFF) measured by MRI at week 48 [1].
Mazdutide and NAFLD in type 2 diabetes after semaglutide
A multicentre, prospective, randomised controlled investigator-initiated trial is evaluating switching to mazdutide in Chinese patients with type 2 diabetes mellitus (T2DM) and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycaemic control. The study background notes that Chinese patients with T2DM are susceptible to visceral fat accumulation, which increases the risk of cardiometabolic diseases and mortality, and that metabolic associated fatty liver disease (MAFLD) is highly prevalent in this population [2].
Sclerostin, irisin and leptin and body composition in Chinese men with obesity
A cross-sectional study examined interactions among sclerostin, irisin and leptin and their associations with body composition and bone metabolism in Chinese men with obesity. The study included 26 men with normal weight and 78 men with obesity. Body composition was measured by dual-emission X-ray absorptiometry; subcutaneous fat, visceral fat, and fat content in the liver and pancreas were determined by magnetic resonance; and serum sclerostin, irisin and leptin were detected by ELISA. Compared with men with normal weight, serum sclerostin, irisin and leptin levels as well as whole-body and spinal bone mineral density differed [3].
BMI versus body fat percentage and IVF outcomes
A prospective observational cohort study is evaluating whether body composition measured by bioelectrical impedance analysis (BIA), including body fat percentage and visceral fat, predicts in vitro fertilisation (IVF) cycle outcomes better than body mass index (BMI). Participants undergoing IVF will have body composition assessed by BIA prior to treatment. Outcomes of interest include ovarian stimulation requirements, number of mature oocytes retrieved, and number of oocytes fertilised [4].
Urolithin A and muscle preservation during restricted eating in obesity
A study is testing whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle programme (nutrition and sleep guidance); half receive Urolithin A and half a matching placebo. The background notes that weight loss can reduce skeletal muscle, especially in people with obesity, and that aging and obesity are linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation [5].
Resistin and visceral fat reduction after sleeve gastrectomy
A study is investigating whether serum resistin levels can predict how much visceral fat a patient will lose following sleeve gastrectomy for morbid obesity. Sleeve gastrectomy reduces stomach size to help patients lose weight and improve metabolic health. The study background states that reducing visceral fat, the fat stored around internal organs, is closely linked to inflammation and conditions such as type 2 diabetes, and that resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat [6].
Barley green and visceral fat area via gut microbiota
A study investigated changes in visceral fat area and associated indicators in individuals with high body fat percentage under intervention with barley green, and explored the mechanism by which barley green influences human visceral fat through gut microbiota analysis. Participants were recruited from the Clinical Nutrition Department of Peking University People's Hospital and randomly assigned to an intervention group or a control group. The intervention group received barley green supplementation combined with a calorie-restricted diet [7].
Ethnic differences in adipose tissue dysfunction and type 2 diabetes
A pilot study is investigating the relationship between type 2 diabetes (T2D) and adipose tissue dysfunction across different ethnic groups. Adipose tissue dysfunction is characterised by abnormal fat distribution, including increased visceral, hepatic, and pancreatic fat, elevated inflammatory biomarkers, and impaired metabolic function. The study background notes that in the UK, T2D prevalence is significantly higher among South Asian and Black African/Caribbean populations than among White Europeans, and that differences in adipose tissue distribution, particularly increased visceral fat accumulation, are thought to contribute [8].
Comparison of visceral fat measures across studies
| Study | Population | Visceral fat measure | Intervention or exposure |
|---|---|---|---|
| NCT07803705 [1] | Overweight or obesity | Pancreatic PDFF by MRI | Mazdutide vs placebo |
| NCT07713992 [2] | T2DM with moderate-to-severe NAFLD | Not specified in excerpt | Switch to mazdutide |
| PMC13443498 [3] | Chinese men with obesity vs normal weight | Visceral fat by MRI | Cross-sectional |
| NCT07765368 [4] | IVF patients | Visceral fat by BIA | Observational |
| NCT07377136 [5] | BMI >30 | Not specified in excerpt | Urolithin A 500 mg vs placebo |
| NCT07564986 [6] | Morbid obesity undergoing sleeve gastrectomy | Visceral fat reduction | Serum resistin |
| NCT06886048 [7] | High body fat percentage | Visceral fat area | Barley green + calorie restriction |
| NCT07666321 [8] | Multiple ethnic groups with T2D | Visceral, hepatic, pancreatic fat | Observational |
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Efficacy of Mazdutide on Fatty Pancreas
- [2] Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
- [3] Serum Bone-, Muscle- and Fat- Derived Factors Sclerostin, Irisin and Leptin Show Different Correlations With Body Composition and Bone Mineral Density in Chinese Men With Obesity: A Cross-Sectional Study.
- [4] BMI Versus Body Fat Percentage - Which is the Better Predictor of Fertility Outcomes in IVF Cycles?
- [5] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.
- [6] Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
- [7] Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
- [8] Ethnic Differences in Adipose Tissue Dysfunction in the Development of Insulin Resistance and Type 2 Diabetes
- [9] Circulating Adipokines, Tissue Receptor Expression, and Body Composition: Clinical Relevance and Disease Stage in Epithelial Ovarian Carcinoma.
- [10] Bitter hop nutraceutical stimulates fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice.
- [11] Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
- [12] Hematopoietic stem cell transplantation-associated partial lipodystrophy.